Nektar Therapeutics (NKTR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$74.19-2.85%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NKTR
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 54.6 | 55.2 | 98.4 | 90.1 | 92.1 | 101.9 | 152.9 | 114.6 | 1,193.3 | 307.7 | 165.4 | 230.8 | 200.7 | 148.9 | 81.2 | 71.5 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 307.7 | 165.4 | 230.8 | 200.7 | 148.9 | 81.2 | 71.5 |
| Cost of Revenues | — | — | 30.7 | 33.8 | 21.6 | 24.9 | 19.5 | 21.4 | 24.4 | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 131.8 | 117.3 | 120.9 | 114.2 | 218.3 | 400.3 | 408.7 | 434.6 | 399.5 | 268.5 | 203.8 | 182.8 | 147.7 | 190.0 | 148.7 | 126.8 |
| Operating Income | (140.7) | (140.1) | (105.2) | (263.7) | (376.2) | (446.1) | (425.1) | (440.0) | 687.9 | (59.6) | (112.9) | (29.4) | (16.5) | (120.1) | (141.2) | (123.9) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | — | — | — | 0.0 | 0.0 | 6.9 | 21.3 | 21.6 | 22.1 | 22.5 | 18.3 | 17.9 | 18.5 | 15.5 | 10.2 |
| Interest & Investment Income | 19.2 | 10.4 | 14.5 | 19.0 | 6.8 | 2.7 | — | — | — | — | — | — | — | 0.7 | 2.3 | 2.2 |
| Net Interest Expenses | — | — | — | — | (6.8) | (2.7) | — | — | — | — | — | — | — | 17.7 | 13.2 | 8.0 |
| Other Non-Operating Income / Expenses | (12.4) | (15.4) | (14.0) | (12.6) | 11.2 | (77.2) | (18.8) | (0.0) | (5.2) | (36.4) | (39.8) | (51.3) | (37.9) | (39.6) | (30.2) | (9.0) |
| Asset Writedown | — | — | — | — | 65.8 | 0.0 | 0.0 | — | — | — | — | 0.0 | — | — | — | — |
| EBT, Incl. Unusual Items | (153.1) | (155.5) | (119.2) | (276.3) | (365.0) | (523.3) | (443.9) | (440.1) | 682.7 | (96.1) | (152.6) | (80.7) | (54.4) | (159.8) | (171.4) | (133.0) |
| Income Tax Expense | 0.1 | (0.1) | (0.2) | (0.2) | 3.2 | 0.6 | 0.5 | 0.6 | 1.4 | 0.6 | 0.9 | 0.5 | (0.5) | 2.2 | 0.4 | 1.0 |
| Net Income | ||||||||||||||||
| Net Income | (157.1) | (164.1) | (119.0) | (276.0) | (368.0) | (524.0) | (444.4) | (440.7) | 681.3 | (96.7) | (153.5) | (81.2) | (53.9) | (162.0) | (171.9) | (134.0) |
| Per Share | ||||||||||||||||
| Basic EPS | (4.75) | (9.73) | (0.58) | (1.45) | (1.97) | (2.86) | (2.49) | (2.52) | 4.02 | — | — | — | — | — | — | — |
| Diluted EPS | (4.75) | (9.73) | (0.58) | (1.45) | (1.97) | (2.86) | (2.49) | (2.52) | 3.78 | — | — | — | — | — | — | — |
| Revenue per Share | 1.65 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 33.1 | 16.9 | 205.7 | 190.0 | 187.1 | 183.3 | 178.6 | 175.0 | 169.6 | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 33.1 | 16.9 | 205.7 | 190.0 | 187.1 | 183.3 | 178.6 | 175.0 | 180.1 | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | (139.1) | (100.8) | (255.9) | (363.1) | (432.0) | (410.9) | (426.9) | 698.8 | (44.9) | (97.5) | (16.5) | (3.6) | (105.9) | (126.7) | (109.0) |
| EBIT | (140.7) | (140.1) | (105.2) | (263.7) | (376.2) | (446.1) | (425.1) | (440.0) | 687.9 | (59.6) | (112.9) | (29.4) | (16.5) | (120.1) | (141.2) | (123.9) |
| Effective Tax Rate | -0.0% | — | — | 0.1% | -0.9% | -0.1% | -0.1% | -0.1% | 0.2% | -0.6% | -0.6% | -0.6% | 0.9% | -1.4% | -0.2% | -0.8% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.